Effects of metformin on QT and QTc interval dispersion of diabetic rats;Os efeitos da metformina sobre a dispersão do intervalo QT e QTc de ratos diabéticos

Arquivos Brasileiros de Cardiologia

Volumn 90, Issue 4, 2008, Pages

  Costa, Eunice Cristina Da Silva ^a,b   Gonçalves, Antonio Ari ^a   Areas, Miguel Arcanjo ^a   Morgabel, Rafael Gustavo Birochi ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b NONE   (Brazil)

Author keywords

Diabetes mellitus, experimental; Electrocardiography; Metformin

Indexed keywords

ALLOXAN; GLUCOSE; METFORMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MARKER; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEART REPOLARIZATION; MALE; NONHUMAN; QT DISPERSION; RAT; RR INTERVAL; TREATMENT OUTCOME;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HEART CONDUCTION SYSTEM; HYPOGLYCEMIC AGENTS; LONG QT SYNDROME; MALE; METFORMIN; MODELS, ANIMAL; RATS; RATS, WISTAR;

EID: 44849096288     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2008000400004     Document Type: Article

References (42)

1. Paulson D. The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res. 1997; 34: 104-12.
2. Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyorala K. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. Diabetologia. 2004; 47 (12): 2118-28.
3. Tomaselli GF, Beuckelmann DJ, Calkins HG, Berger RD, Kessler PD, Lawrence JH, et al. Sudden cardiac death in heart failure: the role of abnormal repolarization. Circulation. 1994; 90: 2534-9.
4. Pye MP, Cobbe SM. Mechanism of ventricular arrhythmias in cardiac failure and hypertrophy. Cardiovasc Res. 1992; 26: 740-50.
5. Sgarbossa EB, Barold SS, Pinski SL, Wagner GS, Pahlm O. Twelve-lead electrocardiogram: the advantages of an olderly frontal lead display including lead-AVR. J Electrocardiol. 2004; 37 (3): 141-7.
6. Rocha e Silva M. As bases fisiológicas da eletrocardiografia. In: Aires MM. Fisiologia. Rio de Janeiro: Guanabara Koogan; 1999.
7. Arildsen H, May O, Christiansen EH, Damsgaard EM. Increased QT dispersion in patients with insulin-dependent diabetes mellitus. Int J Cardiol. 1999; 71: 235-42.
8. Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrythmia risk in patients with long QT intervals. Br Heart J. 1990; 63: 342-4.
9. Shimoni Y, Severson D, Giles W. Thyroid status and diabetes modulate regional differences in potassium currents in rat ventricle. J Physiol. 1995; 488 (Pt 3): 673-88.
10. Sawicki PT, Kiwitt S, Bender R, Berger M. The value of QT interval dispersion for identification of total mortality risk in non-insulin dependent diabetes mellitus. J Intern Med. 1998; 243: 49-56.
11. Christensen PK, Gall MA, Major-Pedersen A, Sato A, Rossing P, Breum L, et al. QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes. Scand J Clin Lab Invest. 2000; 60: 323-32.
12. Dristas A, Gilligan D, Nihoyannopoulus P, Oakley CM. Amiodarone reduces QT dispersion in patients with hypertrophic cardiomyopathy. Int J Cardiol. 1992; 36: 345-9.
13. Brown DW, Giles WH, Greenlund KJ, Valdez R, Croft JB. Impaired fasting glucose, diabetes mellitus and cardiovascular disease risk factors are associated with prolonged QTc duration: results from the Third National Health and Nutrition Examination Survey. J Cardiovasc Risk. 2001; 8: 227-33.
14. Bailey CJ. Insulin resistance and antidiabetic drugs. Biochem Pharmacol. 1999; 58: 1511-20.
15. Fisman EZ, Tenenbaum A, Motro M, Adler Y. Oral antidiabetic therapy in patients with heart disease. Herz. 2004; 29: 290-8.
16. An D, Kewalramani G, Chan JK, Qi D, Ghosh S, Pulinilkunnil T, et al. Metformin influences cardiomyocyte cell death by pathways that are dependent and independent of caspase-3. Diabetologia. 2006; 49 (9): 2174-84.
17. Fisman EZ, Tenenbaum A, Benderly M, Goldbourt U, Behar S, Motro M. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology. 1999; 91 (3): 195-202.
18. Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care. 1996; 19 (1): 64-6.
19. Yajima K, Shimada A, Hirose H, Kasuga A, Saruta T. "Low dose" metformin improves hyperglycemia better than acarbose in type 2 diabetics. Rev Diabet Stud. 2004; 1 (2): 89-94.
20. Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther. 2005; 27 (10): 1548-61.
21. Higuchi M, Miyagi K, Nakasone J, Sakanashi M. Role of high glycogen in underperfused diabetic rat hearts with added norepinephrine. J Cardiol Pharm. 1995; 26: 899-907.
22. Donthi RV, Ye G, Wu C, McClain DA, Lange AJ, Epstein PN. Cardiac expression of kinase-deficient 6-phosphofructo-2-kinase/fructose-2,6- bisphosphatase inhibits glycolysis, promotes hypertrophy, impairs myocyte function, and reduces insulin sensitivity. J Biol Chem. 2004; 279 (46): 48085-90.
23. Arad M, Benson DW, Perez-Atayde AR, McKenna WJ, Sparks EA, Kanter RJ, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest. 2002; 109 (3): 357-62.
24. Steiner DF, Rauda V, Williams RH. Severe ketoacidosis in the alloxan diabetic rats. Endocrinology. 1961; 68: 809-15.
25. Scherer J. Action of alloxan on the pancreas of the guinea pig. Acta Anat (Basel). 1955; 23: 350-79.
26. Oliveira MA, Costa LS, Martins VS, Tress JC, Aldrighi JM, Wajngarten M, et al. Efeito da terapia de reposição hormonal e do raloxifeno a curto prazo sobre o intervalo QTc e dispersão de QTc em mulheres idosas com hipertensão arterial sistêmica. Rev SOCERJ. 2005; 18 (1): 77-81.
27. Sarkar BC, Chauhan UPS. A new method for determining micro quantities of calcium in biological materials. Anal Biochem. 1967; 20: 155-66.
28. Misra P, Chakrabarti R. The role of AMP kinase in diabetes. Indian J Med Res. 2007; 125 (3): 389-98.
29. Zou MH, Kirkpatrick SS, Davis BJ, Nelson WG, Schlattner U, Neumann D, et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. J Biol Chem. 2004; 279 (42): 43940-51.
30. Gonçalves AA, da Silva EC, Brito IJL, da Silva CA, Wiernsperger N. Metformin interacts with training to lower glycemia and to increase glycogen stores in diabetic rats. Diabetologia. 1999; 42 (Suppl): 52A.
31. Lecrere I, Woltersdorf WW, da Silva Xavier G, Rowe RL, Cross SE, Korbutt GS, et al. Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab. 2004; 286: E1023-E1031.
32. Kefas BA, Cai Y, Kerckhofs K, Ling Z, Martens G, Heimberg H, et al. Metformin-induced stimulation of AMP-activate protein kinase in β-cells impairs their glucose responsiveness and can lead to apoptosis. Biochem Pharmacol. 2004; 68 (3): 409-16.
33. Stith BJ, Woronoff K, Wiernsperger N. Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin. Biochem Pharmacol. 1998; 55 (4): 533-6.
34. Shimoni Y, Severson D, Ewart HS. Insulin resistance and the modulation of rat cardiac K(+) currents. Am J Physiol Heart Circ Physiol. 2000; 279 (2): H639-49.
35. Feuvray D, Lopaschuk GD. Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovasc Res. 1997; 34: 113-20.
36. Sá R, Perez C. Dispersão do QT: seu significado clínico. Rev SOCERJ. 2004; 17 (3): 183-91.
37. Howarth FC, Jacobson M, Shafiullah M, Adeghate E. Long-term effects of streptozotocin-induced diabetes on the electrocardiogram, physical activity and body temperature in rats. Exp Physiol. 2005; 90 (6): 827-35.
38. Brodsky WA, Rapoport S, West CD. The mechanism of glycosuric diuresis in diabetic man. J Clin Invest.1950; 29: 1021-32.
39. Kitabchi AE, Wall BM. Diabetic ketoacidosis. Med Clin North Am. 1995; 79: 9-37.
40. Punske BB, Rossi S, Ershler P, Rasmussen I, Abel ED. Optical mapping of propagation changes induced by elevated extracellular potassium ion concentration in genetically altered mouse hearts. J Electrocardiol. 2004; 37 (Suppl): 128-34.
41. + channel gene expression in diabetic rat ventricle: isoform switching between Kv4.2 and Kv1.4. Am J Physiol Heart Circ Physiol. 2001; 281: H1800-H1807.
42. Kiewiet RM, Ponssen HH, Janssens ENW, Fels PHW. Ventricular fibrillation in hypercalcaemic crisis due to primary hyperparathyroidism. Neth J Med. 2004; 62 (3): 94-6.